Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Leukemia|July 16, 2015
Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomasS K A Divakar, M V Ramana Reddy, S C Cosenza, et al.
Journal of Medicinal Chemistry|May 17, 2012
(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studiesM V Ramana Reddy, Balaiah Akula, Stephen C Cosenza, et al.
Blood|May 27, 2004
Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogenJames S Song, Irma M Sainz, Stephen C Cosenza, et al.
Oncogene|September 15, 2005
Inactivation of ELF/TGF-beta signaling in human gastrointestinal cancerVaralakshmi Katuri, Yi Tang, Blair Marshall, et al.
Gastroenterology|May 31, 2012
A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humansGerold Bongers, Luciana R Muniz, Michelle E Pacer, et al.
Stem Cells (Dayton, Ohio)|August 9, 2014
Myb permits multilineage airway epithelial cell differentiationJie-Hong Pan, Tracy L Adair-Kirk, Anand C Patel, et al.
Molecular Cancer|June 7, 2021
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockadeChi Yan, Nabil Saleh, Jinming Yang, et al.
Genes & Cancer|August 19, 2010
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive InhibitionShashidhar S Jatiani, Stephen C Cosenza, M V Ramana Reddy, et al.
Cancer Research|February 14, 2016
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple MyelomaDeepak Perumal, Pei-Yu Kuo, Violetta V Leshchenko, et al.
Journal of Medicinal Chemistry|June 12, 2013
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agentsM V Ramana Reddy, Muralidhar R Mallireddigari, Venkat R Pallela, et al.
Pageof 11